Consensus 8c. Cuts FY25 revenue view to $807M-$823M from $840M-$860M, consensus $846.39M. Cuts FY25 adjusted EBITDA view to $19M-$27M from $25M-$35M. Updated guidance reflects Q1 results and the current business outlook.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- Myriad Genetics reports Q1 adjusted EPS (3c), consensus (5c)
- Myriad Genetics announces survey results on depression, anxiety
- MYGN Upcoming Earnings Report: What to Expect?
- Myriad says GeneSight Psychotropic Test led to fewer hospitalizations in study
- Myriad Genetics price target lowered to $9 from $11 at BofA